ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Beovu Lawsuits

Beovu lawsuits claim the drug’s manufacturer failed to warn patients and doctors about potential vision side effects. People who took Beovu and suffered vision loss, retinal vasculitis, occlusive retinal vasculitis and other vision problems may qualify to file a lawsuit for compensation.

Beovu (brolucizumab-dbll) is a prescription medication approved by the U.S. Food and Drug Administration to treat wet age-related macular degeneration (AMD). It’s administered by injection into the eye.

From its approval in October 2019 to February 2020, doctors have administered about 46,000 Beovu injections, Novartis told Healio.

In February 2020, the American Society of Retina Specialists (ASRS) shared an update with its members about reports of 14 cases of vasculitis in patients who took Beovu, according to Novartis’ statement to Healio. Vasculitis is inflammation of the vascular branches of arteries in the retina.

Of those 14 cases, 11 people suffered occlusive retinal vasculitis. Occlusive retinal vasculitis is a condition that happens when blood vessels in the eye become blocked. The condition may lead to blindness.

After a month, cases increased to 25 cases of retinal vasculitis. Twenty-one of them involved occlusion.

There were no warnings about these specific adverse events on the drug’s prescribing information until June 2020. Lawyers say Novartis put people at risk of vasculitis, occlusive retinal vasculitis and blindness by not warning them.

Novartis stands by Beovu’s safety and efficacy. In a June 2020 statement, the company said these reports are “rare post-marketing safety events.”

Injuries in Lawsuits

Beovu’s prescribing insert lists several vision-related side effects of the drug. The most common are blurred vision, cataracts, eye hemorrhage and blood vessel inflammation in the back of the eye. The original prescribing label didn’t include warnings about retinal vasculitis and retinal occlusion.

After reviewing the information from American Society of Retina Specialists (ASRS), Novartis announced in April 2020 that it would evaluate reports of severe vision loss, retinal artery occlusion and/or vasculitis with Beovu.

The drug maker concluded that “there is a confirmed safety signal of rare adverse events of ‘retinal vasculitis and/or retinal vascular occlusion that may result in severe vision loss.’”

In February 2020, FDA approved Novartis’ label change to include “additional safety information regarding retinal vasculitis and retinal vascular occlusion.”

Beovu vision injuries in lawsuits include:
  • Blindness
  • Occlusive retinal vasculitis
  • Retinal artery occlusion
  • Retinal vasculitis
  • Vision loss

Woman Has Retinal Vasculitis After Beovu

In August 2020, Dr. Srinivas Sai A. Kondapalli of Everett and Hurite Ophthalmic Association in Pittsburgh, Pennsylvania, reported on a case of a 77-year old woman who suffered acute visual acuity loss in her right eye after taking two doses of Beovu. JAMA Ophthalmology published the case report.

Doctors diagnosed the woman with retinal vasculitis. She had previously taken bevacizumab and aflibercept for wet age-related macular degeneration and did not have any eye inflammation with either drug.

Symptoms of Retinal Vasculitis

Retinal vasculitis is a condition that causes inflammation in the retina, the part of the eye that senses light and allows you to see. Potential causes include infectious disease, a neurological disorder or autoimmune disease.

Retinal vasculitis can be aggressive and recurrent. In uncontrolled disease, it can lead to severe vision loss. It progresses through stages.

If retinal vasculitis occurs with occlusion from a blockage in a vein, it can cause sudden blurring or vision loss. Some vision loss starts as a slight blur then gets worse over hours or days.

Symptoms of retinal vasculitis include:
  • Altered color vision
  • Blurring of vision
  • Flashes
  • Floaters (spots or streaks in vision)
  • Metamorphopsia (a defect that causes linear objects, like lines, to look rounded or curvy)
  • Pain
  • Scotoma (partial loss of vision or a blind spot)

Will There Be a Recall?

So far, Novartis and the FDA haven’t mentioned a Beovu recall.

While the FDA approved Novartis’ label change, it did not issue a safety communication to the public or announce any regulatory actions.

Another drug involved in vision loss lawsuits is Elmiron. According to Elmiron lawsuits, the drug’s maker — Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. — failed to warn people that the medication could cause a rare disorder called retinal pigmentary maculopathy.

Like retinal vasculitis, retinal pigmentary maculopathy can cause permanent vision loss.

FDA hasn’t announced a recall for Elmiron or issued a safety announcement. Janssen added a warning for retinal pigmentary maculopathy in June 2020.

Syringe drawing from a medicine vial
Beovu Lawsuits Facts
  1. Defendant Novartis
  2. Injuries in Lawsuits Retinal vasculitis, retinal artery occlusion, occlusive retinal vasculitis, vision loss and blindness
  3. Status Lawyers are investigating cases and there are no trials or settlements yet.

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • Member of American Medical Writers Association (AMWA) and former Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By

6 Cited Research Articles

Drugwatch.com writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. American Academy of Ophthalmology. (2019, December 16). Retinal vasculitis. Retrieved from https://eyewiki.aao.org/Retinal_Vasculitis#Symptoms
  2. Cleveland Clinic. (n.d.). Retinal vein occlusion. Retrieved from https://my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo
  3. Kondapalli, S.S.A. (2020, August 6). Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2768911
  4. Linneham, R. (2020, February 25). Novartis responds to ASRS update on safety of Beovu. Retrieved from https://www.healio.com/news/ophthalmology/20200225/novartis-responds-to-asrs-update-on-safety-of-beovu
  5. Novartis. (2020, April 8). Novartis completes safety review and initiates update to the Beovu prescribing information worldwide. Retrieved from https://www.novartis.com/news/novartis-completes-safety-review-and-initiates-update-beovu-prescribing-information-worldwide
  6. Novartis. (2020, June 11). US FDA approves updated Novartis Beovu label, to include additional safety information. Retrieved from https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's sponsors support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617